FDA-Approved Cemiplimab-rwlc is Effective in the Treatment of Patients with Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) and Patients with Locally Advanced CSCC Who Are Not Candidates for Curative Surgery or Curative Radiation